KR20160033220A - 베타-3-아드레날린 수용체 작용제와 함께 데스모프레신을 포함하는 방법 및 조성물 - Google Patents

베타-3-아드레날린 수용체 작용제와 함께 데스모프레신을 포함하는 방법 및 조성물 Download PDF

Info

Publication number
KR20160033220A
KR20160033220A KR1020167004515A KR20167004515A KR20160033220A KR 20160033220 A KR20160033220 A KR 20160033220A KR 1020167004515 A KR1020167004515 A KR 1020167004515A KR 20167004515 A KR20167004515 A KR 20167004515A KR 20160033220 A KR20160033220 A KR 20160033220A
Authority
KR
South Korea
Prior art keywords
desmopressin
administered
beta
hours
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020167004515A
Other languages
English (en)
Korean (ko)
Inventor
시모어 에이치. 페인
사무엘 헤르슈코비츠
Original Assignee
알러간, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 알러간, 인코포레이티드 filed Critical 알러간, 인코포레이티드
Priority to KR1020217025792A priority Critical patent/KR20210103589A/ko
Publication of KR20160033220A publication Critical patent/KR20160033220A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A61K38/11—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
KR1020167004515A 2013-07-23 2014-07-23 베타-3-아드레날린 수용체 작용제와 함께 데스모프레신을 포함하는 방법 및 조성물 Ceased KR20160033220A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020217025792A KR20210103589A (ko) 2013-07-23 2014-07-23 베타-3-아드레날린 수용체 작용제와 함께 데스모프레신을 포함하는 방법 및 조성물

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361857431P 2013-07-23 2013-07-23
US61/857,431 2013-07-23
PCT/US2014/047899 WO2015013454A1 (en) 2013-07-23 2014-07-23 Methods and compositions comprising desmopressin in combination with a beta-3 adrenergic receptor agonist

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020217025792A Division KR20210103589A (ko) 2013-07-23 2014-07-23 베타-3-아드레날린 수용체 작용제와 함께 데스모프레신을 포함하는 방법 및 조성물

Publications (1)

Publication Number Publication Date
KR20160033220A true KR20160033220A (ko) 2016-03-25

Family

ID=51299056

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020167004515A Ceased KR20160033220A (ko) 2013-07-23 2014-07-23 베타-3-아드레날린 수용체 작용제와 함께 데스모프레신을 포함하는 방법 및 조성물
KR1020217025792A Ceased KR20210103589A (ko) 2013-07-23 2014-07-23 베타-3-아드레날린 수용체 작용제와 함께 데스모프레신을 포함하는 방법 및 조성물
KR1020247002750A Ceased KR20240015735A (ko) 2013-07-23 2014-07-23 베타-3-아드레날린 수용체 작용제와 함께 데스모프레신을 포함하는 방법 및 조성물

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020217025792A Ceased KR20210103589A (ko) 2013-07-23 2014-07-23 베타-3-아드레날린 수용체 작용제와 함께 데스모프레신을 포함하는 방법 및 조성물
KR1020247002750A Ceased KR20240015735A (ko) 2013-07-23 2014-07-23 베타-3-아드레날린 수용체 작용제와 함께 데스모프레신을 포함하는 방법 및 조성물

Country Status (11)

Country Link
US (2) US9814753B2 (cg-RX-API-DMAC7.html)
EP (1) EP3024474B1 (cg-RX-API-DMAC7.html)
JP (2) JP2016525548A (cg-RX-API-DMAC7.html)
KR (3) KR20160033220A (cg-RX-API-DMAC7.html)
CN (1) CN105579057A (cg-RX-API-DMAC7.html)
AU (1) AU2014293141A1 (cg-RX-API-DMAC7.html)
CA (1) CA2919198A1 (cg-RX-API-DMAC7.html)
DK (1) DK3024474T3 (cg-RX-API-DMAC7.html)
ES (1) ES2910361T3 (cg-RX-API-DMAC7.html)
MX (1) MX2016001030A (cg-RX-API-DMAC7.html)
WO (1) WO2015013454A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101877834B1 (ko) * 2017-04-27 2018-07-12 주식회사 다산제약 미라베그론의 신규한 염 및 이의 제조방법

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0623838D0 (en) * 2006-11-29 2007-01-10 Malvern Cosmeceutics Ltd Novel compositions
PT4104848T (pt) 2009-06-18 2024-01-04 Acerus Pharmaceuticals Usa Llc Administração segura de desmopressina
US9907767B2 (en) 2010-08-03 2018-03-06 Velicept Therapeutics, Inc. Pharmaceutical compositions and the treatment of overactive bladder
CN105579057A (zh) 2013-07-23 2016-05-11 阿勒根公司 包含与β-3-肾上腺素能受体激动剂组合的去氨加压素的方法和组合物
JP2016525147A (ja) 2013-07-23 2016-08-22 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ ５−α還元酵素阻害剤と組み合わせたデスモプレシンを含む方法及び組成物
KR20170097045A (ko) 2014-11-20 2017-08-25 알레간 인코포레이티드 알파-아드레날린성 수용체 길항제와 조합된 데스모프레신을 포함하는 방법 및 조성물
CA2969405A1 (en) 2014-12-03 2016-06-09 Velicept Therapeutics, Inc. Compositions and methods of using modified release solabegron for lower urinary tract symptoms
US20170348263A1 (en) * 2016-06-03 2017-12-07 Velicept Therapeutics, Inc. Compositions and methods of using modified release solabegron for lower urinary tract symptoms

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH495957A (de) 1966-09-15 1970-09-15 Ceskoslovenska Akademie Ved Verfahren zur Herstellung eines antidiuretisch wirksamen Polypeptids
US3989816A (en) 1975-06-19 1976-11-02 Nelson Research & Development Company Vehicle composition containing 1-substituted azacycloheptan-2-ones
US4316893A (en) 1975-06-19 1982-02-23 Nelson Research & Development Co. Vehicle composition containing 1-substituted azacycloalkan-2-ones
US4405616A (en) 1975-06-19 1983-09-20 Nelson Research & Development Company Penetration enhancers for transdermal drug delivery of systemic agents
US4557934A (en) 1983-06-21 1985-12-10 The Procter & Gamble Company Penetrating topical pharmaceutical compositions containing 1-dodecyl-azacycloheptan-2-one
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4783450A (en) 1987-04-13 1988-11-08 Warner-Lambert Company Use of commercial lecithin as skin penetration enhancer
NZ241979A (en) 1991-03-20 1996-01-26 Merck & Co Inc Treatment of benign prostatic hyperplasia using 5alpha-reductase inhibitor and an alpha1-adrenergic recepter blocker
US5534496A (en) 1992-07-07 1996-07-09 University Of Southern California Methods and compositions to enhance epithelial drug transport
ES2249846T3 (es) 1997-12-02 2006-04-01 Archimedes Development Limited Composiciones para administracion nasal.
US7335186B2 (en) 1998-03-13 2008-02-26 Alexander George Brian O'Neil Patient controlled drug delivery device
US6558695B2 (en) 1999-12-16 2003-05-06 Dermatrends, Inc. Topical and transdermal administration of peptidyl drugs using hydroxide releasing agents as permeation enhancers
ES2717656T3 (es) 2000-11-30 2019-06-24 Valeritas Inc Dispositivo con microsonda amovible sustancialmente libre sobre el alojamiento
US7244703B2 (en) 2001-06-22 2007-07-17 Bentley Pharmaceuticals, Inc. Pharmaceutical compositions and methods for peptide treatment
GB0210397D0 (en) 2002-05-07 2002-06-12 Ferring Bv Pharmaceutical formulations
US6945952B2 (en) 2002-06-25 2005-09-20 Theraject, Inc. Solid solution perforator for drug delivery and other applications
ATE500827T1 (de) * 2002-11-07 2011-03-15 Astellas Pharma Inc Mittel zur behandlung von blasenhyperaktivität mit einem essigsäureanilid-derivat als wirkstoff
CA2866501A1 (en) * 2003-11-10 2005-05-26 Allergan, Inc. Pharmaceutical compositions including low dosages of desmopressin
CA2547990C (en) 2003-12-08 2011-08-02 Bentley Pharmaceuticals, Inc. Pharmaceutical compositions and methods for insulin treatment
DE102005016981A1 (de) 2005-04-13 2006-10-19 Bayer Healthcare Ag Kombination zur Therapie bei benigner Prostatahyperplasie
CA2633570A1 (en) 2005-12-21 2007-06-28 Pfizer Products Inc. Pharmaceutical combination of a pde-5 inhibitor and a 5-alpha reductase inhibitor
WO2007083640A1 (ja) * 2006-01-18 2007-07-26 Kyorin Pharmaceutical Co., Ltd. 頻尿及び尿失禁の予防又は治療剤
CA2988753A1 (en) * 2007-08-06 2009-02-12 Serenity Pharmaceuticals, Llc Methods and devices for desmopressin drug delivery
CN101648017A (zh) 2008-08-12 2010-02-17 许洁 用于治疗泌尿生殖系统及下尿路疾病的联合药物组合物
US20110144055A1 (en) 2008-09-04 2011-06-16 Rozmanith Anthony I Health Care
BRPI0923557A2 (pt) 2008-12-22 2016-01-26 Allergan Inc administração de desmopressina intranasal
WO2010075327A1 (en) 2008-12-22 2010-07-01 Serenity Pharmaceuticals Corporation Desmopressin composition
PT4104848T (pt) * 2009-06-18 2024-01-04 Acerus Pharmaceuticals Usa Llc Administração segura de desmopressina
KR20120093859A (ko) * 2009-10-07 2012-08-23 머크 샤프 앤드 돔 코포레이션 베타 ３ 아드레날린 수용체 효능제 및 항무스카린제를 사용하는 조합 요법
US9119878B2 (en) 2010-07-08 2015-09-01 Wellesley Pharmaceuticals, Llc Extended-release formulation for reducing the frequency of urination and method of use thereof
US9522129B2 (en) * 2010-08-03 2016-12-20 Velicept Therapeutics, Inc. Pharmaceutical Combination
WO2012109387A1 (en) 2011-02-08 2012-08-16 Halozyme, Inc. Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia
MX2014011128A (es) 2012-03-19 2015-08-10 Wellesley Pharmaceuticals Llc Formulacion de liberacion prolongada para reducir la frecuencia de miccion y metodo de uso de la misma.
TW201422254A (zh) 2012-11-21 2014-06-16 Ferring Bv 用於速釋及延釋的組成物
GB201312155D0 (en) 2013-07-05 2013-08-21 Ucl Business Plc Therapeutic invention
JP2016525147A (ja) 2013-07-23 2016-08-22 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ ５−α還元酵素阻害剤と組み合わせたデスモプレシンを含む方法及び組成物
CN105579057A (zh) 2013-07-23 2016-05-11 阿勒根公司 包含与β-3-肾上腺素能受体激动剂组合的去氨加压素的方法和组合物
MX2016002705A (es) 2013-09-03 2016-09-06 G2B Pharma Inc Formulacion intranasal para el tratamiento por reanimacion cardiopulmonar (rcp), mantenimiento cardiaco vital (cls), de anafilaxia y/o reacciones anafilactoides.
KR20170097045A (ko) 2014-11-20 2017-08-25 알레간 인코포레이티드 알파-아드레날린성 수용체 길항제와 조합된 데스모프레신을 포함하는 방법 및 조성물

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101877834B1 (ko) * 2017-04-27 2018-07-12 주식회사 다산제약 미라베그론의 신규한 염 및 이의 제조방법

Also Published As

Publication number Publication date
US20180289769A1 (en) 2018-10-11
JP2020109122A (ja) 2020-07-16
KR20240015735A (ko) 2024-02-05
US20150031613A1 (en) 2015-01-29
CA2919198A1 (en) 2015-01-29
AU2014293141A1 (en) 2016-02-18
US10568927B2 (en) 2020-02-25
JP7219736B2 (ja) 2023-02-08
JP2016525548A (ja) 2016-08-25
DK3024474T3 (da) 2022-03-28
WO2015013454A1 (en) 2015-01-29
US9814753B2 (en) 2017-11-14
CN105579057A (zh) 2016-05-11
EP3024474A1 (en) 2016-06-01
EP3024474B1 (en) 2022-01-05
ES2910361T3 (es) 2022-05-12
KR20210103589A (ko) 2021-08-23
MX2016001030A (es) 2016-10-07

Similar Documents

Publication Publication Date Title
JP7219736B2 (ja) Β－３アドレナリン受容体刺激薬と組み合わせたデスモプレシンを含む方法及び組成物
JP2024161452A (ja) アルファ－アドレナリン受容体拮抗薬と組み合わせたデスモプレシンを含む方法及び組成物
EP1397126B9 (en) Use of tramadol for delaying ejaculation
JP2022137252A (ja) ５－α還元酵素阻害剤と組み合わせたデスモプレシンを含む方法及び組成物

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

R11 Change to the name of applicant or owner or transfer of ownership requested

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R11-ASN-PN2301 (AS PROVIDED BY THE NATIONAL OFFICE)

R13 Change to the name of applicant or owner recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R13-ASN-PN2301 (AS PROVIDED BY THE NATIONAL OFFICE)